期刊
ANNALS OF ONCOLOGY
卷 26, 期 7, 页码 1280-1291出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv161
关键词
breast cancer; neoadjuvant systemic therapy; residual disease; pathologic complete response; pathologic assessment; response evaluation
类别
资金
- Breast Cancer Research Foundation (BCRF)
- Cancer Research UK [11010] Funding Source: researchfish
Neoadjuvant systemic therapy ( NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow- up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group- North American Breast Cancer Group ( BIG- NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post- NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response ( pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site ( clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR ( ypT0/ is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/ UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据